Coherus Oncology (CHRS) Accounts Payables (2013 - 2026)
Coherus Oncology (CHRS) posted Accounts Payables of $11.5 million for Q1 2026, up 15.77% sequentially from $9.9 million in Q4 2025, and down 71.95% YoY from $40.9 million in Q1 2025.
Coherus Oncology (CHRS) Accounts Payables (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Accounts Payables for 14 years, with the latest figure at $11.5 million in Q1 2026.
- Quarterly Accounts Payables fell 71.95% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 71.95% YoY) and the FY2025 annual result came in at $9.9 million, down 65.16% from the prior year.
- Accounts Payables climbed to $11.5 million in Q1 2026 per CHRS's latest filing, from $9.9 million in the prior quarter.
- Over five years, Accounts Payables peaked at $76.8 million in Q2 2024 and troughed at $9.9 million in Q4 2025.
- A 5-year average of $27.9 million and a median of $24.9 million in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables slumped 78.3% in 2022, then jumped 274.02% in 2023.
- Over 5 years, Accounts Payables stood at $11.5 million in 2022, then soared by 205.56% to $35.2 million in 2023, then decreased by 19.2% to $28.5 million in 2024, then tumbled by 65.16% to $9.9 million in 2025, then grew by 15.77% to $11.5 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $11.5 million, $9.9 million, and $24.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | 13.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.17 Mn |
| Mar 31, 2026 | 11.48 Mn |
| Dec 31, 2025 | 9.92 Mn |
| Sep 30, 2025 | 24.89 Mn |
| Jun 30, 2025 | 37.62 Mn |
| Mar 31, 2025 | 40.93 Mn |
| Dec 31, 2024 | 28.46 Mn |
| Sep 30, 2024 | 21.89 Mn |
| Jun 30, 2024 | 76.82 Mn |
| Mar 31, 2024 | 38.29 Mn |
| Dec 31, 2023 | 35.22 Mn |
| Sep 30, 2023 | 37.09 Mn |
| Jun 30, 2023 | 29.28 Mn |
| Mar 31, 2023 | 23.23 Mn |
| Dec 31, 2022 | 11.53 Mn |
| Sep 30, 2022 | 9.92 Mn |
| Jun 30, 2022 | 17.49 Mn |
| Mar 31, 2022 | 21.09 Mn |
| Dec 31, 2021 | 16.16 Mn |
| Sep 30, 2021 | 45.71 Mn |